Percutaneous transluminal pulmonary angioplasty for Takayasu arteritis-associated pulmonary hypertension : A single-arm meta-analysis
© 2023 Wiley Periodicals LLC..
BACKGROUND: The efficacy and safety of percutaneous transluminal pulmonary angioplasty (PTPA) for Takayasu arteritis-associated pulmonary hypertension (TA-PH) remain unclear.
OBJECTIVES: To examine the efficacy and safety of PTPA in TA-PH.
METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials Library were searched from inception to August 18, 2022, for articles investigating the efficacy and safety of PTPA for TA-PH. The primary efficacy outcomes were pulmonary vascular resistance (PVR) changes from baseline to re-evaluation and 6-minute walking distance (6MWD). The safety outcome was procedure-related complications.
RESULTS: Five articles comprising 104 patients with TA-PH who underwent PTPA were included. The scores of article quality, as assessed using the methodological index for nonrandomized studies tool, were high, ranging from 13 to 15 points. The pooled treatment effects of PVR (weighted mean difference [WMD]: -4.8 WU; 95% confidence interval [CI]: -6.0 to -3.5 WU; I2 = 0.0%), 6MWD (WMD: 101.9 m; 95% CI: 60.3-143.6 m; I2 = 70.4%) significantly improved. Procedure-related complications, which predominantly present as pulmonary artery injury and pulmonary injury, occurred in 32.0% of the included patients. Periprocedural death occurred in one patient (1.0%, 1/100).
CONCLUSIONS: Patients with TA-PH could benefit from PTPA in terms of hemodynamics and exercise tolerance, at the expense of procedure-related complications. PTPA should be encouraged to enhance the treatment response in TA-PH. These findings need to be confirmed by further studies, ideally, randomized controlled trials.
REGISTRATION: PROSPERO CRD42022354087.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions - 102(2023), 3 vom: 31. Sept., Seite 558-567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Ming-Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Efficacy |
|---|
| Anmerkungen: |
Date Completed 12.09.2023 Date Revised 12.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ccd.30773 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360220495 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360220495 | ||
| 003 | DE-627 | ||
| 005 | 20231226082540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccd.30773 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360220495 | ||
| 035 | |a (NLM)37522190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Ming-Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Percutaneous transluminal pulmonary angioplasty for Takayasu arteritis-associated pulmonary hypertension |b A single-arm meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.09.2023 | ||
| 500 | |a Date Revised 12.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: The efficacy and safety of percutaneous transluminal pulmonary angioplasty (PTPA) for Takayasu arteritis-associated pulmonary hypertension (TA-PH) remain unclear | ||
| 520 | |a OBJECTIVES: To examine the efficacy and safety of PTPA in TA-PH | ||
| 520 | |a METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials Library were searched from inception to August 18, 2022, for articles investigating the efficacy and safety of PTPA for TA-PH. The primary efficacy outcomes were pulmonary vascular resistance (PVR) changes from baseline to re-evaluation and 6-minute walking distance (6MWD). The safety outcome was procedure-related complications | ||
| 520 | |a RESULTS: Five articles comprising 104 patients with TA-PH who underwent PTPA were included. The scores of article quality, as assessed using the methodological index for nonrandomized studies tool, were high, ranging from 13 to 15 points. The pooled treatment effects of PVR (weighted mean difference [WMD]: -4.8 WU; 95% confidence interval [CI]: -6.0 to -3.5 WU; I2 = 0.0%), 6MWD (WMD: 101.9 m; 95% CI: 60.3-143.6 m; I2 = 70.4%) significantly improved. Procedure-related complications, which predominantly present as pulmonary artery injury and pulmonary injury, occurred in 32.0% of the included patients. Periprocedural death occurred in one patient (1.0%, 1/100) | ||
| 520 | |a CONCLUSIONS: Patients with TA-PH could benefit from PTPA in terms of hemodynamics and exercise tolerance, at the expense of procedure-related complications. PTPA should be encouraged to enhance the treatment response in TA-PH. These findings need to be confirmed by further studies, ideally, randomized controlled trials | ||
| 520 | |a REGISTRATION: PROSPERO CRD42022354087 | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Takayasu arteritis | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a percutaneous transluminal pulmonary angioplasty | |
| 650 | 4 | |a pulmonary hypertension | |
| 650 | 4 | |a safety | |
| 700 | 1 | |a Zhu, Yong-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yu-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xi-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yin-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Chun-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Ke-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xian-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xi-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Zhi-Cheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions |d 1999 |g 102(2023), 3 vom: 31. Sept., Seite 558-567 |w (DE-627)NLM101487487 |x 1522-726X |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2023 |g number:3 |g day:31 |g month:09 |g pages:558-567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccd.30773 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2023 |e 3 |b 31 |c 09 |h 558-567 | ||